Pre-hypertension Clinical Trial
Official title:
Association Between Consumption of Different Dosages of Bioactive Wheat Peptides and Blood Pressure (BP) Level and Other Biomarkers of Cardiovascular Disease Risk in Healthy Subjects With High-normal BP: a Double-blind, Cross-over, RCT
Verified date | August 2015 |
Source | University of Bologna |
Contact | Claudio Borghi, MD |
claudio.borghi[@]unibo.it | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this study we will assess the effects of bioactive peptide rich wheat products on blood
pressure and estimated cardiovascular disease risk. This will be a pilot, explorative,
cross-over, randomized double-blind 2 groups x 2-arms controlled, clinical trial. The
intervention will be based on commercially-packaged pasta, which will appear and taste the
same; (i) low dose bioactive peptides vs. (ii) high dose bioactive peptides. Inclusion
Criteria will be: Male and female non-diabetic adult volunteers at increased estimated CV
risk (ESC/EAS SCORE) with SBP 130-139 mmHg and/or DBP 85-90 mmHg); Age included between 40
and 70 years old; Primary prevention for CVD but otherwise in good general health and have
had no major illness in the previous 6-months; Volunteer providing their signed and dated
informed consent form. Exclusion Criteria will be: Severe medical illness/chronic
disease/gastrointestinal pathology (e.g. coeliac disease); Secondary prevention for CVD;
Treatment with drugs potentially affecting BP (including antihypertensive drugs) or other
related CV risk factors; Consumption of nutraceuticals, botanical extracts or other vitamin
supplements; Volunteer diagnosed as being hypertensive A total of 60 participants will be
recruited and following adherence to a standardized diet for a 4-week period, will be
randomly assigned to complete one of 2 treatment sequences by consuming a prescribed quantity
of pasta products for a 4-week period followed by a 4-week washout before random assignment
to the 2nd treatment.
The Primary Outcome will be the modification of office blood pressure (assessed by systolic
and diastolic BP, pulse and mean pressure (mean of 3 standing & sitting measures) and 24-hour
blood pressure.
Additional outcomes include: Anthropometric parameters (Weight, WC, HC, WC/HC, ICO, BMI),
Glucose and Lipid profile (TC, LDL-C, HDL-C, TG, non-HDL cholesterol, risk ratios), Estimated
CVD risk changes (EAS/ESC SCORE Charts), Measures of vascular health (FMD, PWA, PWV, Aix),
Liver and renal functionality biomarkers, 24-h urine collection at baseline of treatment
phase 1 and endpoint of the final phase will be analysed to account for potential confounding
of urinary sodium excretion (intake) As required by the GCPs and GLPs, all the SOPs have
already been established and all the personnel to be involved in the study is continuously
trained in trials with similar outcomes
Status | Unknown status |
Enrollment | 60 |
Est. completion date | March 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 45 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Primary prevention for cardiovascular diseases - Systolic blood pressure 130-139 mmHg and/or Diastolic blood pressure 85-89 mmHg - Estimated cardiovascular risk >5% (Italian Heart Project cards) - Ability of the volunteer to understand the study finalities and to adhere to the study protocol - Signed informed consent Exclusion Criteria: - Secundary prevention for cardiovascular disease or high risk to develop cardiovascular disease - Diabetes mellitus - High level of a single cardiovascular disease risk factor (i.e.: severe hypertension/hypercholesterolemia) - Chronic renal or liver failure - Obesity (Body Mass Index>30 kg/m2) - Coeliac disease or gluten intolerance - Assumption of antihypertensive drugs at antihypertensive dosageā¢ Each medical or surgery condition potentially making difficult or inconstant the volunteer adhesion to the study protocol |
Country | Name | City | State |
---|---|---|---|
Italy | S. Orsola-Malpighi University Hospital | Bologna | BO |
Lead Sponsor | Collaborator |
---|---|
University of Bologna | European Commission |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Anthropometric measurement changes | Height, weight, body mass index, waist circumference, hip circumference, waist/hip ratio, visceral adiposity index, index of central obesity measured from trained personnel following SOPs | 4 weeks | |
Other | Liver parameters modification | 12-hour liver transaminases, gamma-glutamyl-transferase, Lipid Accumulation Product, and Hepatic Steatosis Index evaluated with standardized methods | 4 weeks | |
Other | Renal function parameter modification | 12-hour fasting serum uric acid, creatinine, and estimated glomerular filtration rate (CKD-EPI formula) evaluated with standardized methods | 4 weeks | |
Primary | Office blood pressure modification | Systolic, diastolic, pulse, mean arterial pressure, pulse pressure index, mean of 3 consecutive measurement as for the European guidelines on blood pressure measurement suggestion | 4 weeks | |
Secondary | 24-hour blood pressure modification (ABPM) | Twenty-four hour ambulatory blood pressure monitoring (ABPM) will be performed using a non-invasive automatic monitor (Space Labs, model 90207). For ABPM, patients will be instructed to act and work as normal between 6:00 AM and 10:00 PM and rest or sleep between 10:00 PM and 6:00 AM. Readings were obtained automatically at 15-min intervals throughout a 24-h study period. Separate averages will be obtained for the 24-h, daytime (6:00 AM-10:00 PM) and night-time (10:00 PM-6:00 AM) values. The accuracy of the automatic blood pressure readings will be checked against manual readings taken using a standard mercury sphygmomanometer, twice for each ABPM. Blood pressure were was measured with the patient sitting, before the beginning of the ABPM, and after a 5-min rest period. The accuracy test will be repeated after the end of each 24-h ABPM. | 4 weeks | |
Secondary | Cholesterolemia modification | 12-hour fasting Total, LDL, HDL and non HDL-Cholesterol, evaluated with standardized methods | 4 weeks | |
Secondary | Flow-mediated vasodilation modification | Evaluation of endothelial function by automatic measurement executed with the Vicorder Endopath instrument, already validated in previous publications | 4 weeks | |
Secondary | Fasting glucose modification | 12-hour fasting plasma glucose evaluated with standardized methods | 4 weeks | |
Secondary | Pulse Wave Velocity modification | Evaluation of arterial stiffness measured as Pulse Wave Velocity and related parameters by the Vicorder instrument, already validated in previous publications | 4 weeks | |
Secondary | Triglyceridemia modification | 12-hour fasting triglyceridemia evaluated by standardized lab methos | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03313284 -
Respiratory Muscle Training and Intermittent Hypoxia: Additive Health Effects?
|
N/A | |
Completed |
NCT01741779 -
Diet and Whole-body Vibration Training on Cardiovascular and Autonomic Function
|
N/A | |
Withdrawn |
NCT01074918 -
Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00288158 -
Primary Prevention of Hypertension in Obese Adolescents
|
Phase 2 | |
Completed |
NCT01190319 -
Study: Effects of Strawberries on Blood Pressure
|
N/A | |
Completed |
NCT01008176 -
Restoring Sleep Homeostasis to Lower Blood Pressure
|
N/A | |
Recruiting |
NCT04543656 -
Personalized Blood Pressure Care Using IoMTs and Artificial Intelligence
|
N/A | |
Completed |
NCT03168789 -
Tension Tamer Randomized Control Trial
|
N/A | |
Completed |
NCT00553969 -
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00170937 -
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
|
Phase 4 | |
Completed |
NCT01741766 -
The Effects of Stretching Training on Arterial Function and Autonomic Control
|
N/A | |
Completed |
NCT02143817 -
Whole Body Vibration Combined With L-citrulline Supplementation on Cardiovascular Function and Body Composition
|
N/A | |
Terminated |
NCT00388388 -
Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects
|
Phase 2 | |
Completed |
NCT02148458 -
Short Term Intermittent Fasting and Mediterranean Diet
|
N/A | |
Terminated |
NCT01349114 -
Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects
|
Phase 4 | |
Completed |
NCT02038179 -
Center of Research Translation (CORT) Project 2
|
Phase 2/Phase 3 | |
Completed |
NCT01202175 -
Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension
|
Phase 4 | |
Completed |
NCT00970931 -
Hypertension Prevention in Pre-Hypertensive Individuals
|
Phase 3 | |
Completed |
NCT01841840 -
The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke
|
N/A | |
Not yet recruiting |
NCT01364675 -
Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects
|
N/A |